Dianthus Therapeutics, Inc.

NASDAQ:DNTH

Biotechnology

Healthcare
$84.83 -1.25%

-$1.03 today

Market cap
$4.78B
Beta
0.07
P/E (TTM)
-343.0
EPS (TTM)
-$0.24
52W Low $16.64High $96.50

Volume 0.89M

Average 0.82M

Income Statement

Follow revenue through to earnings.

Revenue

$2.04M

FY 2025 · Annual

-67.3% YoY

Operating Income

-$177.93M

FY 2025 · Annual

Net Income

-$162.34M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.48M6.42M2.83M6.24M2.04M
Cost of Revenue00000
Gross Profit1.48M6.42M2.83M6.24M2.04M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development12.61M29.38M32.84M83.11M145.64M
Selling, General & Admin1.96M6.74M18.16M24.99M34.33M
Operating Expenses14.56M36.12M51M108.1M179.97M
Depreciation & Amortization2.02M147K355K412K428K
EBITDA(11.09M)(28.33M)(43.2M)(84.56M)(161.91M)
EBITDA Margin-751.3%-441.5%-1528.7%-1356.2%-7952.3%
Operating Income(13.09M)(29.71M)(48.17M)(101.86M)(177.93M)
Operating Margin-886.6%-462.9%-1704.7%-1633.7%-8739.3%
Interest Income100K1.15M4.76M17.37M16.12M
Interest Expense00000
Other Income / Expenses(23K)1.23M4.62M16.9M15.6M
Income Before Tax(13.11M)(28.48M)(43.56M)(84.97M)(162.34M)
Pre-Tax Margin-888.1%-443.8%-1541.2%-1362.8%-7973.3%
Income Tax Expense00000
Net Income(13.11M)(28.48M)(43.56M)(84.97M)(162.34M)
Net Margin-888.1%-443.8%-1541.2%-1362.8%-7973.3%
EPS (Basic)(3.82)(7.60)(8.45)(2.55)(4.20)
EPS (Diluted)(3.82)(7.60)(8.45)(2.55)(4.20)
Weighted Avg Shares3.43M3.75M5.15M33.31M37.79M
Weighted Avg Shares (Diluted)3.43M3.75M5.15M33.31M37.79M

DNTH Earnings Waterfall · TTM

NASDAQ:DNTH · Revenue to Net Income

Key Ratios

EPS$-0.13
Gross Margin95.9%
Net Margin2442.9%
P/E Ratio-14.5
P/S Ratio6280.7

Analysis

$1.9M of revenue converted into -$29.9M of net income for the selected period. Gross margin is 95.9% and net margin is 2442.9%, showing how much revenue survives after costs and taxes. EPS is $-0.13, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
8-KCurrent reportNov 4, 2026
10-QQuarterly reportNov 4, 2026
SC 13GSC 13G filingOct 30, 2026
4Statement of changes in beneficial ownershipSep 18, 2026

How much revenue does DNTH generate?

Dianthus Therapeutics, Inc. (DNTH) reported $2.04M of revenue in fiscal 2025.

Is DNTH profitable?

Dianthus Therapeutics, Inc. (DNTH) reported -$162.34M of net income, with a net margin of -7973.3%.